The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

SPRAVATO® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain.6 The mechanism by which esketamine exerts its antidepressant effect is ...

SPRAVATO® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain.6 The mechanism by which esketamine exerts its antidepressant effect ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...

However, Spravato contains a different form of ketamine than the version that is used intravenously—a chemical sibling called esketamine. In the years since its approval, Spravato and ketamine ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...